RESOMER RP d 335 is a poly(D,L-lactide)-b-poly(ethylene glycol) diblock introduced into continuous microsphere lines as the oil-phase film former in a 20 L jacketed vessel paired with a rotor-stator high-shear mixer operating at 4,000–12,000 rpm. The addition ratio on total solids is set at 10–30% w/w active pharmaceutical ingredient relative to RESOMER RP d 335, while the copolymer is dissolved in dichloromethane at 5–20% w/w and dispersed into an aqueous continuous phase containing 1.0–2.5% w/v poly(vinyl alcohol) 18-88 at an oil-to-water volume ratio of 1:10 to 1:20. Solvent extraction is performed at 25°C under 250 rpm overhead agitation for 4–8 h; the hardened microspheres are collected through a 20 µm stainless steel sieve, washed with WFI until residual poly(vinyl alcohol) content falls below 0.5% w/w, and lyophilized with 5% w/v mannitol. Particle size is measured by laser diffraction according to ISO 13320:2020, with Dv50 controlled between 10 µm and 40 µm for deep intramuscular injection; sub-10 µm fractions increase initial release surface area and larger fractions provoke injection-site irritation. Regulatory anchors for this sterile lyophilized microsphere vial include USP <71> sterility, USP <85> bacterial endotoxin using the dose-dependent acceptance equation, ICH Q3C dichloromethane residual limits below 600 ppm, and ISO 10993-1 biocompatibility evaluation for long-term implant contact. Terminal saturated steam sterilization is avoided because the D,L-lactide ester backbone hydrolyzes rapidly above 80°C in aqueous environments. The terminal dosage form is a single-dose vial containing 10–40 mg microsphere powder plus mannitol, reconstituted immediately before deep intramuscular or subcutaneous injection with WFI or a sodium carboxymethylcellulose vehicle.

What Limits the Burst Index in Subcutaneous In Situ Forming Depots?

In situ forming depots based on RESOMER RP d 335 require a final organic solution loading of 30–45% w/w copolymer, 5–15% w/w active molecule, and 55–65% w/w N-methyl-2-pyrrolidone to achieve the viscosity window for injection through a 27G needle; polymer loading below 30% w/w produces a fragmented depot with poor in vivo integrity, while loading above 45% w/w raises dynamic viscosity above 200 mPa·s at 25°C and extends filtration time through a 0.22 µm PVDF membrane. The production line dissolves RESOMER RP d 335 and the active molecule in NMP under 1,000 rpm orbital mixing to avoid air entrainment, then passes the solution through a 0.45 µm PVDF prefilter and a 0.22 µm final filter before aseptic filling into ISO 11040-4 prefilled syringe systems. Phase inversion occurs after injection into subcutaneous fluid; in vitro release is characterized in PBS at 37°C using USP <711> apparatus 4 flow-through cells, with burst index defined as percentage released at 24 h relative to total dose. For water-soluble actives above 15% w/w loading, the burst index frequently exceeds 30% because the PEG block swells and forms aqueous channels before the D,L-lactide matrix has fully precipitated; this is the principal formulation threshold rather than a copolymer solubility limit. Compliance anchors include ICH Q3C NMP class 2 limits with a permitted daily exposure of 5.3 mg/day, USP <467> residual solvent screening by headspace gas chromatography, USP <71> sterility, and ISO 10993-1 for long-term subcutaneously implanted depot contact. The terminal finished product is a prefilled syringe or single-dose vial containing a clear, filter-sterilized organic solution that forms a solid or semisolid depot upon injection and releases over 4–12 weeks depending on NMP exchange rate and D,L-lactide block length.

For single-dose intravitreal microsphere suspensions that must pass USP <789> particulate matter limits for ophthalmic solutions, RESOMER RP d 335 is dissolved in ethyl acetate at 10–20% w/v and combined with a corticosteroid or anti-VEGF active at 8–20 wt% relative to copolymer. The oil phase is emulsified into an aqueous continuous phase containing 1.0% w/v poly(vinyl alcohol) and 0.5% w/v sodium chloride at 15–25°C; ethyl acetate is removed under 100 mbar vacuum at 30°C for 2–4 h, and the hardened microspheres are wet-sieved through a 25 µm sieve to eliminate larger particulates that would violate intravitreal particle size constraints. After washing with WFI, the microspheres are lyophilized with 5% w/v trehalose to protect the PEG corona from aggregation during reconstitution. Particle size is verified by laser diffraction per ISO 13320:2020, with Dv99 controlled below 25 µm; gamma irradiation is avoided because radiolysis of the PEG block generates peroxide species that would accelerate D,L-lactide chain scission and release shift during storage. Compliance anchors include USP <71> sterility, USP <789> ophthalmic particulate matter, ICH Q3C ethyl acetate class 3 limit of 5000 ppm, and ISO 10993-1 ocular biocompatibility evaluation. The terminal finished product is a single-dose intravitreal injection vial containing lyophilized microspheres plus trehalose, reconstituted immediately before pars plana administration.

When a Tangential Flow Filtration Cassette Retains PEG-PLA Micelles After Acetone Nanoprecipitation

For parenteral oncology or anti-infective nanocarriers, RESOMER RP d 335 is added to the acetone phase at 1–5% w/w total solids, with a polymer-to-drug weight ratio of 10:1 to 25:1; the acetone solution is injected into 10 volumes of WFI at 20–25°C under 300 rpm impeller agitation to induce micelle self-assembly. The resulting nanosuspension is concentrated and diafiltered through a 100 kDa MWCO Pellicon 3 Ultracel tangential flow filtration cassette at a transmembrane pressure of 0.5–1.5 bar and crossflow of 5–10 L/min/m² for 6–10 diavolumes, then lyophilized with 5% w/v sucrose or trehalose. Control of the acetone addition rate is critical; injection faster than 5 mL/min into the aqueous phase produces Z-average diameters above 100 nm and polydispersity above 0.25, while injection slower than 1 mL/min exposes the D,L-lactide block to interfacial hydrolysis before micelle stabilization is complete. Particle size is measured by ISO 22412:2017 dynamic light scattering; the release specification for intravenous administration sets Z-average between 25 nm and 80 nm with a polydispersity index below 0.20. Compliance includes ICH Q3C acetone class 3 limit of 5000 ppm, USP <787> subvisible particle testing, USP <71> sterility, and ISO 10993-4 hemocompatibility for blood-contacting use. The terminal finished product is a sterile single-use glass vial containing lyophilized micelle powder that is reconstituted with 5% dextrose or WFI to 1–5 mg/mL before intravenous infusion.

Hot-Melt Extrusion Through a 1.0 mm Die: Residence Time Distribution and Implant Diameter Uniformity

Subcutaneous implant rods based on RESOMER RP d 335 are produced on a co-rotating twin-screw extruder with an L/D ratio of 25:1 and a single-hole die diameter of 1.0 mm; the formulation addition ratio is 10–40 wt% active molecule and 60–90 wt% copolymer, with no external plasticizer because the PEG block provides sufficient melt plasticization at barrel set points between 65°C and 90°C. The downstream process uses screw speeds of 20–60 rpm, melt pressures from 10 bar to 40 bar, and a cooling belt set to 4°C; puller speed is adjusted from 0.5 m/min to 2.0 m/min to maintain diameter uniformity within ±5% of the 1.0 mm target. Residence time distribution in the extruder is controlled by feed rate and screw speed; operation above 90°C causes measurable transesterification and lactide monomer generation, while operation below 65°C increases melt viscosity above 10,000 Pa·s, stalls the screw, and produces die-face tearing. The extrudate is cut into 1–3 cm lengths and packaged in nested trays; because no organic solvent is used, residual solvent testing under ICH Q3C is limited to trace amounts from cleaning agents that must be validated below permitted daily exposure. Compliance anchors include ISO 10993-5 in vitro cytotoxicity, ISO 10993-10 irritation and delayed-type hypersensitivity, USP <71> sterility, and ASTM F2902-16 characterization guidance for absorbable polymeric implants. The terminal finished product is a sterile single-use subcutaneous implant rod of 0.8–2.0 mm diameter and 1–3 cm length for sustained release over 1–6 months.

With an acetonitrile-dissolved polymer phase and a 5% w/v sucrose aqueous phase cooled to 2°C, RESOMER RP d 335 is loaded at a polymer-to-drug ratio of 10:1 to 20:1 and a total solute concentration of 2–10 mg/mL acetonitrile; after 3,000 rpm high-shear dispersion for 2 min, the organic solvent is stripped at 30°C under 100 mbar vacuum and the product is extruded through a 0.22 µm polycarbonate membrane. The resulting micelle dispersion is lyophilized with 5% w/v sucrose to yield a cake that is reconstituted with WFI or 5% dextrose to 1–5 mg/mL drug. Aseptic processing is required because autoclaving would hydrolyze the D,L-lactide block and because the PEG block may crystallize and aggregate during terminal heat exposure. Compliance anchors include ICH Q3C acetonitrile class 2 limit of 410 ppm, USP <787> subvisible particle testing, USP <71> sterility, and ISO 10993-4 hemocompatibility. The terminal finished product is a sterile single-use glass vial containing lyophilized micelle powder stored at 2–8°C and intended for intravenous infusion over 30–120 min after reconstitution.